1. Home
  2. KN vs TLX Comparison

KN vs TLX Comparison

Compare KN & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Knowles Corporation

KN

Knowles Corporation

HOLD

Current Price

$30.13

Market Cap

2.5B

ML Signal

HOLD

Logo Telix Pharmaceuticals Limited American Depositary Shares

TLX

Telix Pharmaceuticals Limited American Depositary Shares

HOLD

Current Price

$10.57

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KN
TLX
Founded
1946
2015
Country
United States
Australia
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.2B
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
KN
TLX
Price
$30.13
$10.57
Analyst Decision
Buy
Strong Buy
Analyst Count
3
4
Target Price
$22.33
$21.13
AVG Volume (30 Days)
569.3K
211.1K
Earning Date
04-23-2026
08-19-2026
Dividend Yield
N/A
N/A
EPS Growth
118.94
N/A
EPS
0.50
N/A
Revenue
$593,200,000.00
N/A
Revenue This Year
$9.40
N/A
Revenue Next Year
$6.98
N/A
P/E Ratio
$62.48
$150.33
Revenue Growth
7.17
N/A
52 Week Low
$15.43
$6.28
52 Week High
$31.95
$18.99

Technical Indicators

Market Signals
Indicator
KN
TLX
Relative Strength Index (RSI) 62.17 62.59
Support Level $23.97 $9.46
Resistance Level N/A $11.28
Average True Range (ATR) 1.06 0.32
MACD 0.25 -0.07
Stochastic Oscillator 70.08 57.14

Price Performance

Historical Comparison
KN
TLX

About KN Knowles Corporation

Knowles Corp is engaged in the manufacturing of micro-acoustic microphones and balanced armature speakers, audio solutions, high-performance capacitors, and radio frequency filtering products. It operates in two segments; the Precision Devices segment specializes in the design and delivery of high-performance capacitor products and RF solutions; and Medtech & Specialty Audio segment designs and manufactures microphones and balanced armature speakers used in applications. The majority of its revenue comes from the Precision Devices. Geographically, it operates in United States, Asia, Other Americas, Europe and Others, out of which United States generates maximum revenue.

About TLX Telix Pharmaceuticals Limited American Depositary Shares

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Share on Social Networks: